FEEDS
Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin® Program / Grant Supports Personalized Anti-cancer Approach on Path to Clinic
Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and ... weiter zur Meldung von Pieris AG
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual Meeting
San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the ... weiter zur Meldung von Pieris AG
Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of ... weiter zur Meldung von Pieris AG
Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin(R) Pipeline Development
Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive ... weiter zur Meldung von Pieris AG
EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
Freising, Germany (ots) - - Consortium Will Receive Six Million Euro from Seventh Framework Programme The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining ... weiter zur Meldung von Pieris AG
Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin(R) PRS-080 Hepcidin Antagonist Drug Program / Data to be presented at BioIron Society Meeting in Vancouver
Freising (ots) - Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 ... weiter zur Meldung von Pieris AG
Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin(R) Therapeutics
Freising, Germany (ots) - Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply ... weiter zur Meldung von Pieris AG
Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference
Freising (ots) - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium ... weiter zur Meldung von Pieris AG
Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-Conference
Freising, Germany (ots) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, ... weiter zur Meldung von Pieris AG
Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates ... weiter zur Meldung von Pieris AG
Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
Freising-Weihenstephan (ots) - Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which ... weiter zur Meldung von Pieris AG
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti-VEGF PRS-050 is first Anticalin tested in humans
Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's ... weiter zur Meldung von Pieris AG
Pieris AG Appoints Chief Scientific Officer
Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both ... weiter zur Meldung von Pieris AG
Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
Freising-Weihenstephan (ots) - Novel Approach with PRS-110 Shows Dose-dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin" compound, which targets the c-Met receptor, demonstrating a ... weiter zur Meldung von Pieris AG
Pieris Appoints a New CEO / Appointment will bring substantial deal-making expertise to the company
Freising-Weihenstephan, Germany (ots) - Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr. Yoder ... weiter zur Meldung von Pieris AG
Pieris reports preclinical development progress of its next generation VEGF antagonist / PRS-050 program on track to commence clinical trials as planned
Freising-Weihenstephan, Germany (ots) - Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the ... weiter zur Meldung von Pieris AG
Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
Freising-Weihenstephan, Germany (ots) - Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug delivery ... weiter zur Meldung von Pieris AG
Pieris reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist / Expansion of management team announced to support program success
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin® ... weiter zur Meldung von Pieris AG
WACKER bestätigt Skalierbarkeit der Anticalin®-Produktion mit der E.coli-Sekretionstechnologie und wird den ersten klinischen Kandidaten von Pieris PRS-050 herstellen
Freising-Weihenstephan/Jena (ots) - Die Pieris AG, ein biopharmazeutisches Unternehmen spezialisiert auf die Entwicklung von Anticalinen®, einer neuen Klasse von Wirkstoffen aus maßgeschneiderten humanen Bindeproteinen, und die Wacker Biotech GmbH, ... weiter zur Meldung von Pieris AG
Pieris raises EUR 25 M (US$ 38 M) in Series B financing round / New investment round led by OrbiMed Advisors, world?s largest healthcare investment firm
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor OrbiMed ... weiter zur Meldung von Pieris AG
Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin®-based novel cancer therapy
Freising-Weihenstephan (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced the appointment of Dr Angelika Stern as Chief Operating Officer to the Company. ... weiter zur Meldung von Pieris AG
Pieris and Pepscan to identify GPCR-specific Anticalins® using CLIPS[TM] protein mimicry technology
Freising (ots) - Pieris AG (Munich, Germany) and Pepscan Therapeutics (Lelystad, Netherlands) today announced the commencement of a research collaboration aimed at identifying Anticalins® specific for G-Protein Coupled Receptors (GPCRs) and ... weiter zur Meldung von Pieris AG
Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating ... weiter zur Meldung von Pieris AG
Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin®-based protein product candidate
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for ... weiter zur Meldung von Pieris AG
Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully ... weiter zur Meldung von Pieris AG
